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Background: Beneficial effects of azithromycin in cystic fibrosis (CF) have been reported, however, its mechanism of action remains unclear. The
present study aimed at investigating the effect of azithromycin on CF airway epithelial cells.
Methods: Primary cultures of purified tracheal epithelial cells from F508del and normal homozygous mice were established. Responses to
lipopolysaccharide from Pseudomonas aeruginosa (LPS, 0.1 µg/ml) on mRNA expression of neutrophil-related chemokines, pro- and anti-
inflammatory cytokines were investigated in the presence or the absence of azithromycin (1 µg/ml).
Results: CF airway epithelial cells showed upregulation of MIP-2 and KC responses to LPS, and azithromycin failed to downregulate these
responses. In contrast, in CF cells, azithromycin increased KC and TNF-α expression under non-stimulated and LPS-stimulated conditions,
respectively. In non-CF cells, the macrolide potentiated the LPS response on MIP-2 and on IL-10.
Conclusions: Airway epithelial cells contribute to the dysregulated immune processes in CF. Azithromycin rather stimulates cytokine expression
in CF airway epithelial cells.
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Despite remarkable progress in understanding the pathogen-
esis of cystic fibrosis (CF), the clear mechanism connecting
abnormal CF transmembrane conductance regulator (CFTR)
protein function to chronic bacterial airway infection, including
colonization with Pseudomonas aeruginosa, has not been fully
elucidated. Inflammation and infection account for a progressive
and chronic pulmonary disease, the major cause of morbidity
and mortality in patients with CF. A pathobiologic feature of CF⁎ Corresponding author. Tel.: +32 2 764 67 24; fax: +32 2764 69 32.
E-mail address: teresinha.leal@uclouvain.be (T. Leal).
1 Equal contributors.
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doi:10.1016/j.jcf.2009.03.003pulmonary disease is a profound tissue neutrophil accumulation
which is accompanied by elevated levels of pro-inflammatory
mediators such as interleukin-(IL)-8, IL-6, tumor necrosis
factor-(TNF)-α and by reduced levels of anti-inflammatory
mediators, such as IL-10 [1–4]. Airway epithelial cells may also
contribute to the inflammatory process in CF lung disease.
Although recent studies have shown that epithelial cells are an
important source of IL-8, a CXC chemokine acting as a
neutrophil chemoattractant [5], the concept that inflammatory
gene expression in airway epithelial cells is dysregulated in CF
remains controversial.
Several clinical trials have demonstrated consistent beneficial
effects of azithromycin, a macrolide antibiotic structurally
modified from erythromycin, in respiratory function and qualityd by Elsevier B.V. All rights reserved.
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action of the macrolide is still unclear. Our previous in vivo study
[10], performed in F508del homozygous mice [11], indicates that
azithromycin exerts relevant anti-inflammatory properties in
spontaneous and induced inflammatory responses. We hypothe-
sized that airway epithelial cells participate to the exaggerated
inflammation in CF and that azithromycin modulates inflamma-
tory responses in these cells. In the present work, we analyzed the
immune behavior and the effect of azithromycin in airway
epithelial cells isolated and purified from CF mice comparatively
to those corresponding cells obtained from wild-type animals.
2. Methods
2.1. Animal model
Female CFmice homozygous for the F508del mutation in the
129/FVB outbred background [11] and their wild-type litter-
mates were housed in specific pathogen free conditions with free
access to food and water. To prevent CF intestinal obstruction,
Movicol® (55.24 g/L) (Norgine, Belgium) was administered in
acidified drinking water. The mice were genotyped at 21 days of
age, as previously described [10]. All studies and procedures
were approved by the local Ethics Committee for Animal
Welfare and conformed to the European Community regulations
for animal use in research (CEE no. 86/609).
2.2. In vivo experiments
Bronchoalveolar lavage (BAL) was performed in animals
treated or not with lipopolysaccharide from P. aeruginosa (LPS,
0.1 µg/ml; Sigma-Aldrich), as previously described [10].
2.3. Isolation of epithelial cells
Epithelial cells were isolated and purified from trachea of CF
or wild-type mice. Animals were killed by subcutaneous
injection of 24 mg sodium pentobarbital (Certa, Belgium).
Trachea was excised from the proximal surface of the thyroid
cartilage to the bifurcation of bronchi. Attached tissues were
dissected and trachea was cut open lengthwise. Trachea was
washed three times in PBS and incubated in 10 ml of a digestion
solution containing HBSS medium, 1% penicillin–streptomy-
cin to which 164 U/ml collagenase (Worthington Biochemical,
Lakewood, NJ), 25 µg/ml liberase (Roche Diagnostics Meylan,
France) or 1 mg/ml pronase (Sigma-Aldrich, Saint Louis, MO)
were added. The quality of the enzymatic dissociation wasTable 1
Forward and reward primers (Invitrogen) of amplified mRNA sequences of interest
Forward Reward
5′-CGG CTA CCA CAT CCA AGG AA-3′ 5′-ATA
5′-AGA GGG AAATCG TGC GTG AC-3′ 5′-CAA
5′-GCC TCT TCT CAT TCC TGC TTG-3′ 5′-GGC
5′-GAC GGA CCC CAA AAG ATG AAG-3′ 5′-CTC
5′-CAG AAA ATT GTC CAA AAG ATG CTA AA-3′ 5′-AGG
5′-CCA CCA ACC ACC AGG CTA C-3′ 5′-GCTevaluated by monitoring the number of isolated viable cells by
trypan blue exclusion and by checking cell morphology after
Diff Quick staining. Different combinations of the three
digestion enzymes with different incubation times (2 h or
overnight) and incubation temperatures (37 °C or 4 °C) were
performed. Digestion with pronase used at 1 mg/ml for 60 min
at 37 °C provided the best results with a final cell density of
2.5×105 cells/mouse. Lower density was obtained with
collagenase or liberase (2.0×105 cells/mouse).
At the end of pronase digestion, the cell suspension was
filtered through a 70 µm cell strainer (BD Biosciences, Bedford,
MA) in a 50 ml falcon tube. Cells were resuspended in 10 ml of
an incubation medium composed of equal parts of DMEM and
F-12 medium, spun for 10 min (120 g at 4 °C) and the pellet was
resuspended in 3 ml of the incubation medium. Following 2 h
adherence in 6-well culture plates at 37 °C in an atmosphere of
5% CO2, macrophages and fibroblasts were depleted. Non-
adherent cells were collected by an additional centrifugation
(10 min at 120 g at 4 °C) and pellets were resuspended in BEG
medium (Invitrogen) to reach 2×105 epithelial cells/ml. Cells
(2×105/100 µl) were seeded at 37 °C for 24 h in an atmosphere
of 5% CO2 in 96-well culture plates.
2.4. Immunohistochemistry
After 24 h plating, epithelial cells were identified based on
their expression of cytokeratin and cadherin. For this purpose,
immunostaining techniques were performed using rabbit
antibodies against mouse pancytokeratin and e-cadherin
(Santa Cruz, Heidelberg, Germany). Negative controls were
performed by omitting the primary antibodies. Cells were fixed
in methanol for 2 min, washed in PBS, and incubated in 3%
H2O2 solution for 5 min. Cells were immersed in blocking
solution (Vectastain ABC-AP kit; Vector Laboratories, Burlin-
game, CA) for 15 min, then washed in PBS and incubated
overnight at 4 °C with the primary antibody. Cell preparations
were incubated for 30 min with a biotinylated secondary
antibody (Anti Rabbit IgG; Vectastain) and with Vectastain
Reagent for 30 min. Finally, diaminobenzidine tetrahydro
chloride (DAB; Vectastain) stain was added and the specimens
were analyzed using a microscope and an Axioplan 2 camera
(Zeiss, Welwyn Garden City, UK).
2.5. Treatment of cultured cells
After 24 h seeding, inflammatory responses of tracheal
epithelial cells were monitored after addition for 3 h of LPS to.
Gene
CGC TAT TGG AGC TGG AAT TAC C-3′ 18S RNA
TAG TGATGA CCT GGC CGT-3′ β-actin
CAT TTG GGA ACT TCT CA-3′ TNF-α
TTC GTT GAT GTG CTG CTG TG-3′ IL-1β
ACC CTC AAA AGA AAT TGT ATA GTG-3′ KC
TCA GGG TCAA GGC AA-3′ MIP-2
Fig. 1. Diff Quick staining of tracheal epithelial cell isolated from wild-type
mice under pronase digestion; ciliated cells are shown in the inset (A).
Immunostaining of isolated tracheal epithelial cells for pancytokeratin (B) and
negative control (C). Calibration bars correspond to 50 µm in panels A–C and to
10 µm in the inset.
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anti-inflammatory mediators was assessed by monitoring TNF-
α, CCL-2 (Chemokine C-C motif, ligand 2), IL-1β, NOS-2, KC
(keratinocyte chemoattractant), MIP-(macrophage inflamma-
tory protein)-2; and IL-10, respectively. Azithromycin (Pfizer,
Belgium) 1 µg/ml in b0.1% ethanol was applied to cell cultures
at seeding (24 h) and during treatment with LPS (3 h).
2.6. RNA extraction and mRNA quantification
RNA from tracheal epithelial cells was extracted with
Trizol® Reagent (Invitrogen), according to the manufacturer's
instructions. RNA (122 ng–1 µg) was reverse transcribed using
SuperScript III Reverse Transcriptase (Invitrogen) with
350 picomoles random hexamers (Eurogentec, Belgium) in a
final volume of 25 µl. Resulting cDNA, from wild-type or CF
cell cultures, was then diluted 10× in sterile distilled water and
used as a template in subsequent RT-PCR. Sequences of interest
were amplified using the primers shown in Table 1.
For amplification of mouse IL-10 and CCL-2 sequences, we
had to resort to Taqman pre-designed primer (Applied
Biosystem, Foster City, CA). A relative quantification of
mRNA expression was performed on an ABI 7000 in the
following conditions: 2 min 50 °C, 10 min 95 °C (15 s 95 °C,
1 min 60 °C) ×40. Six serial 1:10 dilutions of a positive control
sample of cDNA were used as standards in each reaction.
Standards and samples (5 µl) were amplified with 300 nM
described primers using Power SYBR Green PCR Master Mix
or with 900 nM of the IL-10 and CCL-2 primers using Taqman
Universal Master Mix (Applied Biosystems) in a total volume
of 25 µl. PCR product specificity was checked by taking a
dissociation curve and by agarose gel electrophoresis. Results
were normalized to the amount of 18S RNA. RT-PCR analyses
were performed in triplicate.
2.7. Cytokine assay
Mouse MIP-2 (Quantikine mouse MIP-2, R&D Systems)
concentrations were measured in the supernatant of epithelial
cell cultures or in BAL fluid samples, using a standard sandwich
ELISA.
2.8. Statistics
Data are presented as means±SEM. Differences were
evaluated using t tests with GraphPad InStat version 3.05 for
Windows 95/NT (GraphPad Software, San Diego, CA).
Statistical significance was considered at Pb0.05.
3. Results
3.1. Purification of airway epithelial cells from CF and
wild-type mice
In order to investigate the immune behaviour of CF airway
epithelial cells, we first developed and validated a primary-
cultured murine epithelial cell system. The efficiency ofdifferent proteases (liberase, pronase and collagenase) and
experimental protocols was compared (see Methods). The use
of 1 mg/ml pronase at 37 °C for 60 min appeared to be the most
appropriate protocol to release viable and purified airway
epithelial cells. Cells stained with Diff Quick appeared, as
classically observed for epithelial cells, uniform with a large
cytoplasm and an undense nucleus (Fig. 1A). Cilia were
observed (Fig. 1A, inset). The degree of cell purification of
cultured epithelial cells was evaluated by immunocytostaining
techniques by using antibodies against e-cadherin and pancy-
tokeratin. Under these conditions, approximately 85% of
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antibody against pancytokeratine (Fig. 1B, C), and e-cadherine
(data not shown).
3.2. Neutrophil related chemokine responses
To investigate whether CF epithelial cells may contribute
to airway inflammation through expression of neutrophil
chemoattractants, we analyzed, in CF and wild-type primary-
cultured tracheal epithelial cells, basal and LPS-stimulated
expression of MIP-2 and KC, two mouse neutrophil-
chemoattractant mediators functionally homologs to the
human IL-8.
Under non-stimulated conditions, no differential increase of
the neutrophil-chemoattractant factors could be observed in
mutant as compared to non-mutant cells, neither on mRNA
expression nor on MIP-2 protein levels (Fig. 2A–B). However,
under LPS stimulation, striking differences could be observed
between CF and wild-type cells. Indeed, after LPS stimulation,
MIP-2 and KC expression levels were significantly higher in CF
cells. MIP-2 mRNA levels were increased by around 20-fold in
wild-type and 100-fold in CF cells (Fig. 2A). KC levels wereFig. 2. mRNA expression of neutrophil-related chemokines [MIP-2 (A–C) and KC (D
type (WT) mice or in the fluid of bronchoalveolar lavage (BAL). Cells were cultured
performed in non-stimulated conditions or 24 h after tracheal instillation of 10 µg/20
data normalized to the expression of 18S RNA. For cell culture experiments, bars rep
isolated and pooled from 3–4 animals. For in vivo experiments, bars represent means
independent experiments for cell cultures or BAL samples, respectively. P values den
wild-type group.increased by 12-fold in wild-type and 20-fold in CF cells
(Fig. 2D). After LPS stimulation, MIP-2 and KC mRNA levels
were found to be significantly higher in CF than in wild-type
cells (Fig. 2A, D). An increase by 30% was observed in MIP-2
protein levels in LPS-stimulated CF cells (Fig. 2B). In CF BAL
samples, MIP-2 protein levels were also increased as compared
to samples obtained from wild-type animals (Fig. 2C).
These data indicate that F508del-CFTR mutation in airways
epithelial cells is associated to exaggerated responses of
neutrophil-chemoattractant factors.
3.3. Pro-inflammatory and anti-inflammatory immune response
To investigate whether CF epithelial cells may also contribute
to airway inflammation in F508del-CF mice through the
expression of pro- and anti-inflammatory cytokines, we
monitored the mRNA expression levels of TNF-α, IL-1β,
NOS-2 and CCL-2, used as pro-inflammatory markers, and
those levels of IL-10, used as anti-inflammatory marker. Under
non-stimulated conditions, no differential increased mRNA
expression could be observed on pro-inflammatory markers
in CF as compared to wild-type cells (Fig. 3A–D). mRNA)] in purified tracheal epithelial cells obtained from F508del-CF (CF) and wild-
in non-stimulated conditions or under stimulation with 0.1 µg/ml LPS. BAL was
g body weight of LPS from Pseudomonas aeruginosa, as described [10]. mRNA
resent means±SEM for 3–4 individual cell cultures obtained from tracheal cells
±SEM for 6 animals per each group. Data illustrate one of 2 or 6 representative,
ote levels of significance measured in CF vs that measured in the corresponding
Fig. 3. mRNA expression of pro-inflammatory [TNF-α (A), IL-1β (B), NOS-2 (C), CCL-2 (D)] and anti-inflammatory [IL-10 (E)] cytokines in purified tracheal
epithelial cells obtained from F508del-CF (CF) and wild-type (WT) mice. Cells were cultured in non-stimulated conditions or under stimulation with 0.1 µg/ml LPS.
Data normalized to the expression of 18S RNA. Bars represent means±SEM for 3–4 individual cell cultures obtained from tracheal cells isolated and pooled from 3–4
animals. Data illustrate one of 2 representative, independent experiments. P values denote levels of significance measured in CF vs that measured in the corresponding
wild-type cultured cells.
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1β, were globally more pronounced under LPS-stimulated
conditions. Indeed, an increase by 2- to 3-fold on mRNA
expression levels was observed in CF and wild-type cells
with comparable magnitude of responses in both cell genotypes
(Fig. 3A–D).
LPS-stimulated epithelial cells expressed about 6-fold higher
levels of IL-10 mRNA in CF than in non-CF cells (Fig. 3E).
Without LPS stimulation, no difference was noticed between
the two cell genotypes.These findings indicate that F508del-CFTR is not associated
to a different pattern of expression of pro-inflammatory
cytokines in tracheal epithelial cells. Stimulation with LPS
was associated to an increased anti-inflammatory IL-10
production by CF cells.
3.4. Effect of azithromycin
In order to investigate whether azithromycin can regulate the
immune activity of airways epithelial cells, tracheal epithelial
Fig. 4. Effect of azithromycin (AZM, 1 µg/ml in b0.1% ethanol) on mRNA expression of chemokines [MIP-2 (A) and KC (B), pro-inflammatory cytokine [TNF-a (C)]
and anti-inflammatory marker [IL-10 (E)] in purified tracheal epithelial cells obtained from F508del-CF (CF) and wild-type (WT) mice. Cells were cultured in non-
stimulated conditions and under stimulation with 0.1 µg/ml LPS. Data normalized to the expression of 18S RNA. Bars represent means±SEM for 3–4 individual cell
cultures obtained from tracheal cells isolated and pooled from 3–4 animals. Cell cultures not treated with azithromycin were exposed to culture medium containing
b0.1% ethanol. Data illustrate one of 2 representative, independent experiments. P values denote levels of significance measured in azithromycin treated cells
compared to the corresponding non-treated cells. Significant P values for comparison between CF vs the corresponding wild-type cells after LPS stimulation are also
indicated.
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to induce anti-inflammatory effects in macrophages from the
same mouse model (unpublished data). After LPS stimulation,
wild-type cells showed an increased MIP-2 response when
treated with azithromycin as compared to not treated cells
(Fig. 4A). The upregulating effect of azithromycin on gene
expression of neutrophil-chemoattractant mediators was con-
firmed on KC, particularly in CF cells in the absence of LPS
stimulation (Fig. 4B). The potentiating LPS response of
azithromycin on MIP-2 was confirmed at the protein level:
MIP-2 reached 77.1±6.6 and 43.6±7.2 pg/ml (p: 0.03) in LPS-
stimulated non-CF cells treated or not with the macrolide.
The effect of azithromycin was also assessed on the mRNA
expression of the pro-inflammatory cytokine TNF-α. In the
absence of stimulation with LPS, treatment with azithromycin
was followed by an increased expression of TNF-α in bothmutant
and non-mutant cells comparatively to the corresponding cell type
not treated with the macrolide (Fig. 4C). No potentiating effect of
azithromycin on TNF-α expression was observed when cell
cultures were treated with LPS. The expression of other pro-inflammatory cytokines assessed (IL-1β and CCL-2) was not
modified by azithromycin (data not shown).
The effect of azithromycin was also assessed on the expression
of the anti-inflammatory cytokine IL-10. In the presence of LPS
stimulation, wild-type cells showed increased responses to
azithromycin on IL-10 expression as compared to those
corresponding cells not treated with the macrolide (Fig. 4D).
Overall our in vitro results demonstrate that azithromycin
was not efficient to downregulate the overexpression of
chemokines and cytokines. In contrast, in the absence of
external stimuli, the macrolide appears to act as a powerful
inducer of gene expression of neutrophil-related mediators,
notably KC and TNF-α. Our data also indicate that azithromy-
cin potentiates the LPS response of MIP-2 and IL-10 expression
in wild-type airway epithelial cells in culture.
4. Conclusions
While previous works [12–14] have established long-term
proliferative cell cultures for studying transepithelial ion
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the development of a purified, functionally intact, short-term
cell culture model for investigating immune properties and
responses. It has been reported in primary-cultured human
airway epithelia that release of pro-inflammatory chemokine IL-
8 decreases with time after seeding [14]. The short-term, non-
mitotic, well-differentiated, ciliated cell culture approach we
developed here provides a high-fidelity in vitro model for
evaluating expression and regulation of multiple key genes
involved in immune processes.
We have previously reported that F508del-CF mice display a
spontaneous inflammation characterized by basal and LPS-
induced neutrophil and macrophage infiltrate [10]. We show
here that LPS-induced chemoattractant factors, MIP-2 and KC,
are upregulated in purified CF airway epithelial cells. These
findings support the concept that inflammation in CF airways is
dysregulated and that airway epithelial cells participate to the
dysregulated inflammatory process in CF. The finding that IL-
10 expression was not found, as it would be expected, decreased
in CF epithelial cells in short-term cultures could be dependent
on kinetics of cytokine responses. Indeed, in our in vivo
experiments [10], IL-10 levels were found to be reduced in CF
animals at 48 h after LPS challenge, whereas initial levels were
similar or higher to those monitored in wild-type animals.
Alternatively, it could be postulated that airway epithelial cells
are not the major motor behind the pro-inflammatory phenotype
and that other cell populations, such as alveolar macrophages,
may essentially contribute to the pro- and anti-inflammatory
imbalance we observed in our F508del-CF mice [10].
The precise biochemical events triggering and regulating
exaggerated chemoattractant responses of CF airway epithelial
cells could not be determined in this work. Studies on IL-8
secretion, performed with airway epithelial cells from CF
patients or cell lines expressing mutant CFTR, have provided
conflicting results varying from increased spontaneous or
induced production to non-affected or even decreased levels
[15–20]. It has been shown that CF airway epithelial cells can
modulate IL-8 production following activation of surface toll-
like receptors by cleaved fragments from neutrophil CXC
receptors [21]. This cycle promotes further neutrophil infiltra-
tion into the airways and favors perpetuation of inflammation.
IL-8 induction should ultimately require a combination of
multiple mechanisms including transcriptional activation of the
gene by nuclear factor-(NF)-κB and activator protein-(AP)-1
pathways [22].
The growing interest in macrolide antibiotics as beneficial
therapeutic agents in CF followed the success of long-term
erythromycin for treating diffuse pan-bronchiolitis, a condition
sharing common features with CF. Apart from its anti-
bactericidal effects, a variety of possible mechanisms of action
of azithromycin have been raised (for review see [23]). We have
previously shown that azithromycin attenuates neutrophil and
macrophage infiltration in airways of F508del-CF mice in both
baseline and LPS-stimulated conditions and inhibits TNF-α and
MIP-2 release in LPS-stimulated inflammation [10]. Consistent
anti-inflammatory effects of macrolides have been demon-
strated on neutrophils [24] and macrophages [25]. However,fewer studies have investigated immune properties of azithro-
mycin in airway epithelial cells. In the present work, we showed
that, as in our in vivo data, azithromycin increases IL-10 levels
in normal but not in CF airway epithelial cells. However,
induction of neutrophil-chemoattractant gene expression (MIP-
2 and KC) and potentiating effect on LPS-induced responses,
particularly for MIP-2, were observed in this work. Our data, in
addition to the finding that TNF-α expression was upregulated
after azithromycin in CF and non-CF epithelial cells, are in
keeping with a preliminary study in which it was reported that
azithromycin induces a potentiating effect on IL-8 in human
airway epithelia under exposure to a bacterial/inflammatory
medium [28]. In this model, azithromycin was used at a dose
10- to 100-fold higher than that used in our work [28]. In
contrast, at a dose 8 times higher than that used in this work,
azithromycin inhibited transcription of pro-inflammatory genes
(IL-8 and TNF-α) in CF airway epithelial cells [26,27].
The demonstration that macrolides time-dependently mod-
ulate pro-inflammatory cytokine secretion [29] may eventually
account for differences among studies. A temporal transition
with polyphasic responses spanning from an earlier pro-
inflammatory to a later non-inflammatory effect of azithromy-
cin on bronchial epithelial cells has been recently suggested
[29]. In another recent report [30], azithromycin failed to inhibit
IL-8 secretion in a CF bronchial cell line. It could be postulated
that the transition from a pro- to a non-inflammatory status may
vary according to cell type and culture conditions. It could also
be proposed that the epithelial chemotactic and pro-inflamma-
tory effect of azithromycin favors infiltration of inflammatory
cells such as neutrophils and macrophages to the airways.
Therefore, these infiltrating cells may account for the final in
vivo anti-inflammatory effect of the macrolide.
Finally, we developed a high-fidelity well-differentiated in
vitro epithelial cell model for evaluating expression and
regulation of multiple key genes involved in immune processes.
Our results clearly show that airway epithelial cells participate
to the dysregulated inflammatory process in CF by over-
expressing chemoattractant factors. Azithromycin induces a
chemoattractant and pro-inflammatory gene expression in
airway epithelial cells possibly explaining that, in some CF
patients, azithromycin effect is ambiguous or inefficient.
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